Aurobindo Pharma Ltd. said it has received Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAl) status from USFDA.
The stock is trading higher by 2.17% in the opening trade today.
“Further to our intimation dated November 6th, 2019 with regard to the USFDA inspection of Unit VIII, API manufacturing facility at Gaddapotharam, Hyderabad, of the company, we would like to inform that the Company has received the Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAl) status from USFDA,” the pharma company said.
Stock view:
Aurobindo Pharma Ltd is currently trading at Rs515 up by Rs10.9 or 2.16% from its previous closing of Rs504.10 on the BSE.
For Quick Trial – 8871888787
or mail us here - support@researchicon.com
or visit - http://www.researchicon.com
Post a Comment